MARKER THERAPEUTICS INC. financial statements, including revenue, expenses, profit, and loss
The total revenue of GX1 for the last quarter is 957.23 k EUR, and it's 292.80% higher compared to the previous quarter. The net income of Q4 23 is -2.48 M EUR.